Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Licensing > BDA202203

B7H3×PD-L1 bsAb

BLA Filing
  • Project profile
    Project name: B7H3×PD-L1 bsAb
    Indications: B7H3+ and PD-L1+/low cancer
    Research phase: CMC development
    Cooperation demands: License-out or co-development
  • Highlights

    1. Clear MoA.
    (1) B7H3 is high expressed on differentiated tumor cells and cancer initiating cells, which plays a major role in cancer metastasis and recurrence, but has restricted distribution in normal tissues.
    (2) PD-L1×B7H3 bsAb can simultaneously block both PD1/PDL1 and B7H3 pathways.
    (3) When combined with PD-1 antibody, competitor’s B7H3 molecule (MGA271) showed superior efficacy to PD-1 antibody in PD-L1 low tumors.

    2. Strong global competitiveness. There is no report of B7H3×PD-L1 bispecific antibody being developed.

    3. B7H3×PD-L1 bsAb has enhanced T cells and ADCC activities.

    Strong global competitiveness.

    4. B7H3×PD-L1 bsAb showed anti-tumor efficacy superior to mAb or combination therapies, or MGA271 in mouse xenograft models.

    B7H3×PD-L1 bsAb has enhanced T cells and ADCC activities

    5. Low toxicity: MTD ≥ 100 mg/kg in cynomolgus monkeys.

    6. Excellent stability and developability.

  • Project Introduction

    1. Asset type: B7H3×PD-L1 bsAb

    2. Modality: BsAb, potentially "first-in-class"

    3. Indication: B7H3 + and PD-L1 +/low cancer

    4. Research phase: CMC development

    5. Research progress:
    1) B7H3×PD-L1 bsAb showed high purity, excellent stability and developability.
    2) CMC studies have been completed.
    3) B7H3×PD-L1 bsAb’s anti-tumor activities were superior to combination therapies and MGA271(a B7H3 mAb in PhaseⅡ) in animal xenograft model.
    4) Pre-toxicity study in cynomolgus monkeys has been completed.

Comments (0)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message